16th Jul 2014 10:05
LONDON (Alliance News) - Silence Therapeutics PLC said Wednesday it has completed the recruitment of patients for its Phase 2a clinical trial of its Atu027 therapy for pancreatic cancer.
Atu027 is a short-interfering ribonucleic acid therapy that targets the expression of the protein PKN3, which Silence said its a "key factor in cancer progression and metastasis".
Ribonucleic acid is a family of larger molecules that can be used to code, decode, regulate and express genes. It has a similar structure to DNA, and can be delivered into the cell to reduce the level at which genetic code is interpreted by the body.
It has enrolled 24 patients for the study, which will be completed in clinics across Germany. The study will evaluate the safety and pharmacokinetics of the treatment when used in combination with standard chemotherapy treatment Gemcitabine.
"The completion of recruitment for this trial, on schedule, is a key milestone in the development of this programme and we are excited to follow the progress and the results of this novel treatment," said Chief Executive Ali Mortazavi in a statement.
Shares in Silence Therapeutics were trading up 0.9% at 227.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L